Question · Q3 2026
Sabahat Khan inquired about the revenue outlook for the nuclear/energy and life sciences segments, specifically if the significant growth in nuclear was anticipated and what factors drive mid-to-high single-digit growth in life sciences. He also asked about the working capital target and the ranking of M&A in capital allocation as leverage improves.
Answer
Interim CFO Anne Cybulski detailed that energy backlog primarily consists of life extension projects and new builds, including a recent fuel fabrication order. CEO Doug Wright added that nuclear involves long-standing CANDU relationships and early-stage SMR activities, which are long-term investments. For life sciences, Anne mentioned custom integration, products, and services, while Doug highlighted pipeline diversity in radiopharma, visual inspection, med tech, and mail-order pharmacy. Regarding capital, Doug stated it's premature to set new working capital targets but acknowledged progress. He confirmed commitment to disciplined M&A, a rich pipeline, and favoring M&A deployment as leverage improves.
Ask follow-up questions
Fintool can predict
ATS's earnings beat/miss a week before the call


